MRSH

Marsh

$0.00

+3.72%
Jul 2, 2026
Bobby Quantitative Model
Marsh McLennan is a global professional services firm operating in the financial services sector, specifically within insurance broking and consulting. The company is a market leader, distinguished by its dual-segment structure encompassing risk and insurance services via Marsh and Guy Carpenter, alongside a consulting division through Mercer and Oliver Wyman. The current investor narrative centers on the firm's resilience and growth trajectory in a complex risk environment, with recent financial trends showing solid revenue expansion, though the stock's significant pullback from its highs has sparked debate about valuation and near-term cyclical pressures.

People also watch

Arthur J. Gallagher & Co.

Arthur J. Gallagher & Co.

AJG

Analysis
Brown & Brown

Brown & Brown

BRO

Analysis
Erie Indemnity Co

Erie Indemnity Co

ERIE

Analysis
Franklin International Core Dividend Tilt Index ETF

Franklin International Core Dividend Tilt Index ETF

DIVI

Analysis
Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

LABU

Analysis

MRSH 12-Month Price Forecast

Historical Price
Current Price $178.54
Average Target $178.54
High Target $205.32099999999997
Low Target $151.759

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Marsh's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.

Average Target

$0.00

8 analysts

Implied Upside

vs. current price

Analyst Count

8

covering this stock

Price Range

$0 - $0

Analyst target range

Buy
2 (25%)
Hold
4 (50%)
Sell
2 (25%)

The stock is covered by 8 analysts, indicating solid institutional interest. The consensus sentiment leans bullish to neutral, with recent actions including a 'Strong Buy' from Raymond James and an 'Overweight' from Barclays, though Mizuho downgraded from 'Outperform' to 'Neutral' in February. The average target price is not explicitly provided in the data, but analyst estimates focus on an average EPS of $12.33 for the coming period, which, when applied to the forward P/E, suggests a valuation framework but not a specific price target; therefore, implied upside cannot be calculated from the given dataset. The target range is reflected in the EPS estimates, with a low of $11.41 and a high of $13.02, representing a spread of about 14%, which indicates a moderate level of uncertainty or variance in growth assumptions among analysts. The pattern of recent ratings shows a mix of reiterations and one notable downgrade, suggesting analysts are closely monitoring the stock's performance amid market volatility, with the overall coverage affirming the company's long-term prospects while acknowledging near-term challenges.

Drowning in data?

Find the real signal!

MRSH Technical Analysis

The stock is in a pronounced downtrend, having declined 23.1% from its 52-week high of $219.71 to its current price of $169.03, positioning it at just 20% of its 52-week range (based on a low of $156.6 and high of $219.71). This positioning near the lower bound of its annual range suggests the stock is deeply oversold, presenting a potential value opportunity, though it also risks being a 'falling knife' if the fundamental backdrop deteriorates further. Recent momentum shows a stark divergence, with a 5.26% gain over the past month sharply contrasting with a 0.08% loss over three months and the severe year-to-date drawdown; this positive one-month move, which significantly outperformed the SPY's -2.86% return, could signal an attempt at mean reversion or a bear market rally within the broader downtrend. Key technical levels are clearly defined, with immediate support at the 52-week low of $156.6 and formidable resistance at the 52-week high of $219.71; a sustained break below support would likely trigger further selling, while reclaiming the $190 level would be a first step toward trend reversal. The stock's beta of 0.61 indicates it has been 39% less volatile than the broader market, which is atypical for a financial services name and may reflect its defensive, cash-generative business model, though recent price action suggests idiosyncratic risks are dominating.

Beta

0.60

0.60x market volatility

Max Drawdown

-17.1%

Largest decline past year

52-Week Range

$157-$216

Price range past year

Annual Return

Cumulative gain past year

PeriodMRSH ReturnS&P 500
1m+10.6%-1.3%
3m+2.3%+13.6%
6m+9.0%
1y+19.1%
ytd+9.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

MRSH Fundamental Analysis

Revenue growth remains positive but has shown sequential deceleration; the most recent Q4 2025 revenue was $6.595 billion, representing a solid 8.7% year-over-year increase, however, this marks a slowdown from the stronger growth rates seen in Q2 and Q1 of 2025. Segment data indicates the Risk and Insurance Services segment, at $3.907 billion, continues to be the larger revenue driver compared to the Consulting segment's $2.465 billion, with both contributing to the overall top-line expansion. The growth trajectory, while healthy, implies the company is not immune to economic cycles, but its diversified service portfolio provides stability. The company is highly profitable, with Q4 2025 net income of $821 million and a robust net margin of 12.45%, supported by a gross margin of 40.29%. Profitability metrics have been stable, with the operating margin for the quarter at 18.48%, consistent with the company's historical profile of high incremental margins on its service-based model. The trailing twelve-month free cash flow of $5.001 billion underscores the business's exceptional cash generation, which is a key fundamental strength. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.42 and a current ratio of 1.10, indicating sufficient liquidity but also a leveraged capital structure that is common for the industry. The strong ROE of 27.55% demonstrates efficient use of shareholder equity, and the substantial free cash flow provides ample capacity for dividends, share buybacks, and strategic acquisitions without straining the financial position.

Quarterly Revenue

$6.6B

2025-12

Revenue YoY Growth

+0.08%

YoY Comparison

Gross Margin

+0.40%

Latest Quarter

Free Cash Flow

$5.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Risk And Insurance Services Segment
Consulting Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is MRSH Overvalued?

Given the consistently positive net income, the primary valuation metric is the P/E ratio. The stock trades at a trailing P/E of 21.88x and a forward P/E of 14.93x, with the significant discount in the forward multiple implying the market expects earnings growth to accelerate or that current earnings are cyclically depressed. Compared to sector averages, Marsh's trailing P/E of 21.88x and EV/EBITDA of 14.75x are not directly comparable without provided industry benchmarks, but the forward P/E of 14.9x appears reasonable for a firm with its growth profile and return metrics. The price-to-sales ratio of 3.35x and price-to-book of 5.98x suggest the market assigns a premium for its intangible assets (client relationships, brand) and high returns on equity. Historically, the current trailing P/E of 21.88x sits below the multi-quarter range observed in the data, which has seen peaks above 36x in 2024; this indicates the stock is trading at a discount to its own historical valuation, which could be justified by the recent price decline and potentially lower growth expectations, or it may represent a relative value opportunity if the business fundamentals remain intact.

PE

21.9x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 16x~44x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

14.8x

Enterprise Value Multiple